vimarsana.com

Latest Breaking News On - Agios pharmaceuticals stock performance - Page 1 : vimarsana.com

Swiss National Bank Has $2.45 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Swiss National Bank Has $2.45 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
defenseworld.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from defenseworld.net Daily Mail and Mail on Sunday newspapers.

Texas
United-states
Switzerland
China
Canada
Swiss
Zurcher-kantonalbank-zurich-cantonalbank
James-william-burns
Brian-goff
Nasdaq
Cantor-fitzgerald
Agios-pharmaceuticals-stock-performance

The Goldman Sachs Group Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

The Goldman Sachs Group Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada
United-states
China
James-william-burns
Jacqualyna-fouse
Jpmorgan-chase-co
News-ratings-for-agios-pharmaceuticals-daily
Agios-pharmaceuticals
China-universal-asset-management-co
Charles-schwab-investment-management-inc
Deutsche-bank
Royal-bank

Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had revenue of […]

United-states
Canada
Brian-goff
James-william-burns
Agios-pharmaceuticals
Agios-pharmaceuticals-inc
Royal-bank
Earnings-history-for-agios-pharmaceuticals
Agios-pharmaceuticals-stock-performance
Agios-pharmaceuticals-company-profile
Insider-activity-at-agios-pharmaceuticals
Goldman-sachs-group

The Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) had its target price raised by The Goldman Sachs Group from $29.00 to $33.00 in a report issued on Friday morning, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on AGIO. JPMorgan Chase & Co. reduced […]

China
Texas
United-states
Canada
Jacqualyna-fouse
Zurcher-kantonalbank-zurich-cantonalbank
James-william-burns
Securities-exchange-commission
Mirae-asset-global-investments-co
Hedge-funds-weigh-in-on-agios-pharmaceuticals
News-ratings-for-agios-pharmaceuticals-daily
Royal-bank

The Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price target hoisted by equities researchers at The Goldman Sachs Group from $29.00 to $33.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target indicates a potential downside of […]

China
United-states
Canada
James-william-burns
Brian-goff
Goldman-sachs-group
Agios-pharmaceuticals-inc
Agios-pharmaceuticals-stock-performance
Mirae-asset-global-investments-co
Securities-exchange-commission
Oak-ridge-investments
Cantor-fitzgerald

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.